What does LEDA Pharma do?

LEDA Pharma is a pharmacy in Bierbeek. Private Limited, started on 19 April 2010, 1 establishment.

What is the address of LEDA Pharma?

The registered office of LEDA Pharma is located at Dorpsstraat 29, 3360 Bierbeek.

Is LEDA Pharma still active?

Yes. According to the CBE (30 October 2026) LEDA Pharma is active, legal situation “Normale toestand”, started on 19 April 2010.

Is LEDA Pharma registered on Peppol?

Yes, LEDA Pharma is registered on the Peppol network with ID 0208:0825107833.

What is the enterprise number of LEDA Pharma?

The enterprise number of LEDA Pharma is BE0825107833.

When was LEDA Pharma founded?

LEDA Pharma was founded on 19 April 2010.

Who are the directors of LEDA Pharma?

According to the 2025 annual accounts, the directors of LEDA Pharma are: Farmacoach AD BV.

Is LEDA Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 April 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did LEDA Pharma make in 2025?

LEDA Pharma posted a profit after taxes of € 6,990 in financial year 2025.

What is the revenue of LEDA Pharma?

As a small company, LEDA Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 21,846.

LEDA Pharma (Private Limited) - Bierbeek - BE0825107833

Dossier LEDA Pharma, printed on 30 October 2026 from databakkes.be/en/0825107833/leda-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 14 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

LEDA Pharma from Bierbeek, company number BE0825107833, closed financial year 2025 with a result of € 6,990 after tax. For that financial year LEDA Pharma recorded a gross margin of € 21,846 and equity of € -51,021. Compared with financial year 2024, the result moved from € 4,907 to € 6,990. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Caution

€ -51,021

▲ € 6,990 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 6,990

▲ 42% vs 2024

Profit after tax over the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -57,221.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 140,286

▼ 9% vs 2024

€ 14,175 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 145

▼ 48% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 21,651 Gross margin 2022: € 21,651 First fiscal year in the series	€ 21,022 Gross margin 2023: € 21,022 ▼ 3% vs 2022 (€ 21,651) Unfavourable step	€ 21,054 Gross margin 2024: € 21,054 Unchanged (€ 21,022) Favourable step	€ 21,846 Gross margin 2025: € 21,846 ▲ 4% vs 2024 (€ 21,054) Favourable step	▲ 4%
Profit after taxes	€ 6,064 Profit after taxes 2022: € 6,064 First fiscal year in the series	€ 5,188 Profit after taxes 2023: € 5,188 ▼ 14% vs 2022 (€ 6,064) Unfavourable step	€ 4,907 Profit after taxes 2024: € 4,907 ▼ 5% vs 2023 (€ 5,188) Unfavourable step	€ 6,990 Profit after taxes 2025: € 6,990 ▲ 42% vs 2024 (€ 4,907) Favourable step	▲ 42%
Equity	€ -68,106 Equity 2022: € -68,106 First fiscal year in the series	€ -62,918 Equity 2023: € -62,918 ▲ € 5,188 vs 2022 (€ -68,106) Favourable step	€ -58,011 Equity 2024: € -58,011 ▲ € 4,907 vs 2023 (€ -62,918) Favourable step	€ -51,021 Equity 2025: € -51,021 ▲ € 6,990 vs 2024 (€ -58,011) Favourable step	▲ € 6,990
Total debts	€ 202,601 Total debts 2022: € 202,601 First fiscal year in the series	€ 170,465 Total debts 2023: € 170,465 ▼ 16% vs 2022 (€ 202,601) Favourable step	€ 157,232 Total debts 2024: € 157,232 ▼ 8% vs 2023 (€ 170,465) Favourable step	€ 142,813 Total debts 2025: € 142,813 ▼ 9% vs 2024 (€ 157,232) Favourable step	▼ 9%
Cash	€ 28,604 Cash 2022: € 28,604 First fiscal year in the series	€ 653 Cash 2023: € 653 ▼ 98% vs 2022 (€ 28,604) Unfavourable step	€ 306 Cash 2024: € 306 ▼ 53% vs 2023 (€ 653) Unfavourable step	-
Land & buildings	€ 102,377 Land & buildings 2022: € 102,377 First fiscal year in the series	€ 94,277 Land & buildings 2023: € 94,277 ▼ 8% vs 2022 (€ 102,377) Unchanged	€ 86,177 Land & buildings 2024: € 86,177 ▼ 9% vs 2023 (€ 94,277) Unchanged	€ 78,077 Land & buildings 2025: € 78,077 ▼ 9% vs 2024 (€ 86,177) Unchanged	▼ 9%
Retained profit	€ -74,306 Retained profit 2022: € -74,306 First fiscal year in the series	€ -69,118 Retained profit 2023: € -69,118 ▲ € 5,188 vs 2022 (€ -74,306) Favourable step	€ -64,211 Retained profit 2024: € -64,211 ▲ € 4,907 vs 2023 (€ -69,118) Favourable step	€ -57,221 Retained profit 2025: € -57,221 ▲ € 6,990 vs 2024 (€ -64,211) Favourable step	▲ € 6,990
Bank debt	€ 181,709 Bank debt 2022: € 181,709 First fiscal year in the series	€ 168,083 Bank debt 2023: € 168,083 ▼ 7% vs 2022 (€ 181,709) Favourable step	€ 154,276 Bank debt 2024: € 154,276 ▼ 8% vs 2023 (€ 168,083) Favourable step	€ 140,286 Bank debt 2025: € 140,286 ▼ 9% vs 2024 (€ 154,276) Favourable step	▼ 9%
Balance sheet total	€ 134,495 Balance sheet total 2022: € 134,495 First fiscal year in the series	€ 107,547 Balance sheet total 2023: € 107,547 ▼ 20% vs 2022 (€ 134,495) Unchanged	€ 99,221 Balance sheet total 2024: € 99,221 ▼ 8% vs 2023 (€ 107,547) Unchanged	€ 91,792 Balance sheet total 2025: € 91,792 ▼ 7% vs 2024 (€ 99,221) Unchanged	▼ 7%

Key figures of LEDA Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to LEDA Pharma?

What happened at LEDA Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 31, 2026 New annual accounts for financial year 2025: profit of € 6,990 (▲ 42% vs 2024). Source: NBB ↗
Apr 19, 2010 New establishment in Bierbeek. KBO
Apr 19, 2010 Start of the company according to the CBE. KBO

In short

From € 6,064 profit in 2022 to € 6,990 profit in 2025.

Best year ever: 2025, with € 6,990 profit.

Original PDFs at the National Bank ↗

Management

FARMACOACH AD 100%

The stake of FARMACOACH AD comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

LEDA Pharma

Behind LEDA Pharma is Farmacoach AD BV. The shares are held by FARMACOACH AD (100%).

Directors

According to the 2025 annual accounts

Farmacoach AD BV

Director · represented by Annelies Drappier

Shareholders

FARMACOACH AD

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Dorpsstraat 29

3360 Bierbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0825.107.833
VAT number: BE 0825.107.833
Registered office: Dorpsstraat 29, 3360 Bierbeek
Names & denominations: LEDA Pharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 19 April 2010
Peppol: Active · Active since 27 Mar 2026
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗